Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...

As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals (NASDAQ: RXRX) is a relatively small player in the biotech industry. The same is true in artificial intelligence (AI), a market where it is barely on the map, given the giant ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

For three weeks last May, employees of the AI giant Nvidia and Recursion Pharmaceuticals slept on the floor of a data center in Salt Lake City. They were there to build a machine that Recursion, a ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...